Gary Amseian

Gary Amseian

Auto-generated profile, based on publicly available information

Gary Amseian

Radiology Department, Hospital Clínic de Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2025 in Insights into Imaging
Verified
Journal Article
Open access
GAGary Amseian
Gary Amseian
FAFrancisco Aya
Francisco Aya
CPCamilo Pineda
Camilo Pineda
SGSofía González-Ortiz
Sofía González-Ortiz
JMJuan-Andrés Mora
Juan-Andrés Mora
LOLaura Oleaga
Laura Oleaga
Immunotherapy, particularly immune checkpoint inhibitors, plays a crucial role in the treatment of brain metastases in various primary cancers. Response assessment encompasses atypical patterns, including pseudoprogression, hyperprogression, or dissociated response, which present greater complexity than classical patterns defined by standardized response assessment criteria. Additionally, intracranial adverse events like hypophysitis or encephalitis may resemble tumor progression. Accurate evaluation and management of brain metastases during immunotherapy requires that radiologists are familiar with both classical and atypical response patterns, as well as potential intracranial adverse events. Brain MRI and advanced imaging techniques serve as essential tools for this purpose. Critical relevance statement: Assessing brain metastases response to immunotherapy accurately is fundamental for therapeutic decision-making. Radiologists must recognize classical and atypical responses and adverse events associated with immunotherapy to ensure optimal patient management. Key Points: Immunotherapy response assessment in brain metastases is complex due to atypical patterns including pseudoprogression, hyperprogression, and dissociated responses. Immunotherapy-induced intracranial adverse events, such as hypophysitis and encephalitis, must be accurately identified. Brain MRI, complemented by advanced imaging techniques (perfusion MRI, MRS, and amino acid PET), is crucial for distinguishing these complex scenarios. Graphical

16 October 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
MFMarcel Figueras
Marcel Figueras
LMLourdes Mengual
Lourdes Mengual
MIMercedes Ingelmo-Torres
Mercedes Ingelmo-Torres
FCFiorella Lizzeth Roldan Chavez
Fiorella Lizzeth Roldan Chavez
BPBernat Padullés
Bernat Padullés
AAAntonio Alcaraz
Antonio Alcaraz
Background/Objectives: Currently, the prediction of disease recurrence after radical prostatectomy (RP) in localized prostate cancer (PCa) relies on clinicopathological parameters, which lack accuracy in predicting clinical outcomes. This study focused on evaluating the utility of cfDNA levels and fragmentation patterns as prognostic biomarkers in progressive prostate-specific antigen (PSA) patients, including those with persistent PSA and biochemical recurrence (BR), after primary treatment in localized PCa patients. Methods: Twenty-nine high-risk localized PCa patients were enrolled in the study between February 2022 and May 2023. Blood samples were obtained before robotic RP. cfDNA concentration and fragment size were quantified using the Quant-it PicoGreen dsDNA Assay kit and Agilent 2200 TapeStation System, respectively. Results: The mean PSA value at diagnosis was 9.4 ng/mL. Seven patients (24.1%) had stage pT2 and 22 (75.9%) pT3. Nine patients (31%) had detectable PSA at the first PSA control six weeks after surgery, and four patients (20%) had BR during a mean follow-up of 18.4 months. No associations were found between cfDNA levels or fragmentation patterns and clinicopathological data. Although not statistically significant, patients with detectable PSA levels post-surgery exhibited higher cfDNA levels and shorter fragments compared with those with undetectable PSA. Conclusions: Our study indicated a tendency toward more fragmented cfDNA levels in PCa patients with persistent PSA. Strikingly, biochemical recurrent PCa patients exhibited similar cfDNA levels and fragmentation patterns compared to non-recurrent patients. Further studies exploring liquid biopsy-derived biomarkers in localized PCa patients are needed to elucidate their clinical utility in predicting PSA persistence.

18 December 2024 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
GAGary Amseian
Gary Amseian
MFMarcel Figueras
Marcel Figueras
JMJoel Mases
Joel Mases
LMLourdes Mengual
Lourdes Mengual
MRMaria J Ribal
Maria J Ribal
SVSergi Vidal-Sicart
Sergi Vidal-Sicart
Prostate cancer recurrence following primary treatment poses a significant clinical challenge, particularly when detected through biochemical recurrence at low PSA levels. Conventional imaging modalities often fail to localize the disease at this early stage. PSMA PET has demonstrated superior sensitivity in detecting recurrent lesions, even in patients with low PSA. Concurrently, liquid biopsy, through analysis of cell-free DNA (cfDNA), offers a minimally invasive approach for monitoring disease. There is scarce evidence about the association between liquid biopsy and PSMA PET/CT findings. This study aimed to assess the correlation between liquid biopsy and tumor burden assessed by PSMA PET/CT in early recurring prostate cancer patients. PSMA PET/CT and liquid biopsies of 32 patients in biochemical recurrence were analyzed. 12 patients (37.5%) had no PSMA PET-measurable disease. Four patients (12.5%) presented local recurrence, seven (21.9%) had recurrence in pelvic lymph nodes, one of whom also had local recurrence. Nine patients (28.1%) presented metastatic recurrence, with or without local or nodal recurrence. PSA levels correlated with molecular imaging data (p < 0.05), including whole body PSMA-TV, whole body PSMA-TL, whole body SUVmean and whole body SUVmax. The mean cfDNA fragment size fraction was inversely correlated with tumour burden measured with whole body PSMA-TV, with a Spearman correlation coefficient of -0.451 and a p-value of 0.009. No correlation was found between cfDNA concentration and PET-PSMA data. This prospective study demonstrated a statistically significant negative correlation between cfDNA fragmentation patterns and PSMA PET/CT volumetric parameters in patients with presumed localized prostate cancer with early biochemical recurrence. These findings underscore the potential of liquid biopsy as a biomarker and a complementary tool to PSMA PET/CT to assess disease progression during the follow-up of these patients.

13 March 2024 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
GAGary Amseian
Gary Amseian
JAJuan-Ramon Ayuso
Juan-Ramon Ayuso

15 January 2025 in Case Reports in Surgery
Verified
Journal Article
Open access
GAGary Amseian
Gary Amseian
APAlexandre Soler Perromat
Alexandre Soler Perromat
ATAlba Torroella
Alba Torroella
LSLia Sisuashvili
Lia Sisuashvili
PEPaula Escarcena
Paula Escarcena
GRGerard Rafart
Gerard Rafart
Intussusception in adults is rare and poses a diagnostic challenge, often due to neoplastic causes. Metastatic melanoma is known to spread to the gastrointestinal tract, especially the small intestine. We report the case of a patient with obstructive symptoms and a history of metastatic melanoma. An emergency abdominal computed tomography (CT) scan identified an obstruction caused by ileoileal intussusception located at the site of a previously described enteric metastasis. Following palliative surgery with ileal resection, two nodular lesions causing intussusception were identified, and pathological examination confirmed intramural metastases from melanoma. In adult patients with obstructive symptoms and a history of melanoma, intussusception secondary to intestinal metastases should be considered in the differential diagnosis.

18 October 2024 in Research Square
Verified
Preprint
Open access
PDF file
GAGary Amseian
Gary Amseian
MFMarcel Figueras
Marcel Figueras
JMJoel Mases
Joel Mases
LMLourdes Mengual
Lourdes Mengual
MRMaria-Jose Ribal
Maria-Jose Ribal
CMCBNM Group Clinic Barcelona Nuclear Medicine
CBNM Group Clinic Barcelona Nuclear Medicine
Background Prostate cancer recurrence following primary treatment poses a significant clinical challenge, particularly when detected through biochemical recurrence at low PSA levels. Conventional imaging modalities often fail to localize the disease at this early stage. PSMA PET has demonstrated superior sensitivity in detecting recurrent lesions, even in patients with low PSA. Concurrently, liquid biopsy, through analysis of cell-free DNA (cfDNA), offers a minimally invasive approach for monitoring disease. There is scarce evidence about the association between liquid biopsy and PSMA PET/CT findings. This study aimed to assess the correlation between liquid biopsy and tumor burden assessed by PSMA PET/CT in early recurring prostate cancer patients. Results PSMA PET/CT and liquid biopsies of 32 patients in biochemical recurrence were analyzed. 12 patients (37.5%) had no PSMA PET-measurable disease. Four patients (12.5%) presented local recurrence, seven (21.9%) had recurrence in pelvic lymph nodes, one of whom also had local recurrence. Nine patients (28.1%) presented metastatic recurrence, with or without local or nodal recurrence. PSA levels correlated with molecular imaging data (p < 0.05), including wbPSMA-TV40, wbTL-PSMA40, wbSUVmean and wbSUVmax. The mean cfDNA fragment size fraction was inversely correlated with tumour burden measured with wbPSMA-TV, with a Spearman correlation coefficient of -0.451 and a p-value of 0.009. No correlation was found between cfDNA concentration and PET-PSMA data. Conclusion This prospective study demonstrated a statistically significant negative correlation between cfDNA fragmentation patterns and PSMA PET/CT volumetric parameters in localized prostate cancer patients with early biochemical recurrence. These findings underscore the potential of liquid biopsy as a biomarker and a complementary tool to PSMA PET/CT to assess disease progression during the follow-up of these patients.